Lv2
200 积分 2021-07-21 加入
A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
2天前
已完结
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
1个月前
已完结
Newly approved cancer drugs in China — innovation and clinical benefit
2个月前
已完结
Molecular portraits of human breast tumours
2个月前
已完结
Delivering precision oncology to patients with cancer
2个月前
已完结
Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies
2个月前
已关闭
The coming decade in precision oncology: six riddles
2个月前
已完结
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
5个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
6个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
